Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) Net Income towards Common Stockholders: 2022-2024

Historic Net Income towards Common Stockholders for Addex Therapeutics (ADXN) over the last 3 years, with Dec 2024 value amounting to $8.0 million.

  • Addex Therapeutics' Net Income towards Common Stockholders fell 112.49% to -$1.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.6 million, marking a year-over-year increase of 269.50%. This contributed to the annual value of $8.0 million for FY2024, which is 168.24% up from last year.
  • As of FY2024, Addex Therapeutics' Net Income towards Common Stockholders stood at $8.0 million, which was up 168.24% from -$11.8 million recorded in FY2023.
  • Over the past 5 years, Addex Therapeutics' Net Income towards Common Stockholders peaked at $8.0 million during FY2024, and registered a low of -$21.8 million during FY2022.
  • Over the past 3 years, Addex Therapeutics' median Net Income towards Common Stockholders value was -$11.8 million (recorded in 2023), while the average stood at -$8.5 million.
  • Data for Addex Therapeutics' Net Income towards Common Stockholders shows a peak YoY spiked of 168.24% (in 2024) over the last 5 years.
  • Over the past 3 years, Addex Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$21.8 million in 2022, then surged by 46.11% to -$11.8 million in 2023, then soared by 168.24% to $8.0 million in 2024.